Blockchain Registration Transaction Record

Creative BioTherapeutics Named 2026 Prix Galien USA Nominee for CBT300

Creative BioTherapeutics named 2026 Prix Galien USA nominee for CBT300, an investigational biologic targeting cancer recurrence and treatment resistance.

This news matters because cancer recurrence and treatment resistance remain two of oncology's most persistent obstacles, affecting countless patients and families. Creative BioTherapeutics' recognition by the Prix Galien USA underscores the urgent need for innovative approaches that address why cancers return after initially successful treatment. The company's progress with CBT300, including an FDA-aligned safety program that could save $1.2 million and accelerate the path to human trials, signals a potential shift in how researchers tackle drug resistance and immune evasion. For patients, the nomination brings hope that new therapeutic strategies may one day improve outcomes and quality of life. Moreover, the founders' personal experiences as a clinician and a biochemist highlight the powerful role of patient-centered science in driving meaningful breakthroughs. As the biotechnology community gathers for the awards, the spotlight on Creative BioTherapeutics may inspire further investment and collaboration in this critical area of unmet need.